[{"orgOrder":0,"company":"Ingenia Therapeutics","sponsor":"Mosaic Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IGT-427","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ingenia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ingenia Therapeutics \/ Mosaic Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Ingenia Therapeutics \/ Mosaic Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by Ingenia Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : IGT-427 is a bispecific antibody that potently blocks VEGF and activates Tie-2. Variants of IGT-427 had long intravitreal half-lives, suggesting potential for a less frequently administered and highly efficacious treatment for diabetic macular edema and ...

                          Product Name : IGT-427

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 05, 2022

                          Lead Product(s) : IGT-427

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Mosaic Biosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank